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OBJECTIVE—Mannose-binding lectin (MBL) is an essential
component of the acute-phase immune response and may thus
play a role in the pathogenesis of type 1 diabetes and diabetic
nephropathy. The serum concentration of MBL is mainly genet-
ically determined, and elevated concentrations have been asso-
ciated with both type 1 diabetes and diabetic nephropathy.
Previous genetic studies have not been conclusive due to the
small number of patients and polymorphisms studied. We inves-
tigated whether MBL2 polymorphisms are associated with type 1
diabetes or diabetic nephropathy and whether patients with
nephropathy have elevated MBL concentrations as indicated
previously. Furthermore, we studied the association between
MBL2 polymorphisms and MBL concentration.
RESEARCH DESIGN AND METHODS—We genotyped 20
MBL2 single nucleotide polymorphisms (SNPs) in a large, well-
characterized Finnish case-control sample consisting of 1,297
patients with type 1 diabetes with or without nephropathy and
701 nondiabetic individuals. The serum concentration of MBL
was available for 1,064 patients.
RESULTS—We found that 19 SNPs were associated with the
MBL concentration (P  3  10
81–7  10
4). MBL concentra-
tions were higher in patients with macroalbuminuria compared
with patients without nephropathy even when the patients were
stratiﬁed by the MBL2 genotypic background in accordance with
previous studies. However, no evidence of association between
any of the SNPs or their haplotype combinations and type 1
diabetes or diabetic nephropathy was observed.
CONCLUSIONS—Although most of the MBL2 SNPs studied
were associated with the MBL concentration, no common vari-
ations (neither single SNPs nor their haplotype combinations)
confer risk of type 1 diabetes or diabetic nephropathy. Diabetes
57:1710–1714, 2009
D
iabetic nephropathy is a common and devas-
tating long-term complication of diabetes, but
its pathogenesis is poorly understood. Low-
grade inﬂammation and complement activa-
tion may, however, play a role in the pathogenesis of
both type 1 diabetes and its complications (1–3). Man-
nose-binding lectin (MBL) is a C-type lectin secreted by
the liver as a component of the acute-phase immune
response, and its binding to carbohydrate structures on
microorganisms activates the MBL complement path-
way (4,5).
Serum concentrations of MBL are signiﬁcantly elevated
in patients with type 1 diabetes (1,2) and even more
elevated in those patients with micro- and macrovascular
complications (6,7). Moreover, high MBL concentrations
early in the course of type 1 diabetes predict later devel-
opment of micro- or macroalbuminuria (8), and MBL
deﬁciency attenuates renal changes in mice with experi-
mentally induced diabetes (9).
The MBL2 gene (OMIM# 154545) on chromosome
10q21 consists of ﬁve exons, four of which are protein
coding (10,11). The serum concentration of MBL is largely
genetically determined (estimated heritability 0.96), and
substantial interindividual variation exists (12). Three non-
synonymous variants in exon 1 named alleles B (G54D/
rs1800450), C (G57E/rs1800451), and D (R52C/rs5030737)
decrease MBL concentration considerably due to incorrect
assembly of the mature MBL protein (13). Furthermore,
several single nucleotide polymorphisms (SNPs),
especially promoter variants H/L (rs11003125), P/Q
(rs7095891), and X/Y (rs7096206), modify the MBL concen-
tration (13). Based on linkage disequilibrium (LD) be-
tween these six promoter and exon 1 variants, seven
common MBL2 haplotypes can be identiﬁed (13).
The low-expression MBL2 variant carriers have an
increased infection risk in situations of impaired immunity
(14), and the role of MBL2 in various autoimmune dis-
eases has been actively studied (15,16). Previous studies
on the relationship between MBL2 and type 1 diabetes
show contradictory results (1,6,17–19). This may be due to
the fact that only a few polymorphisms were studied in
relatively small samples, except in the Finnish study of 470
patients (17). Only the Danish study had nephropathy
status available and reported association between the
high-expression MBL2 genotypes and diabetic nephropa-
thy (6). Thus, the question whether genetic variation in the
MBL2 gene confers susceptibility to type 1 diabetes or
diabetic nephropathy is still warranted.
From the
1Folkha ¨lsan Institute of Genetics, Folkha ¨lsan Research Center,
Helsinki, Finland; the
2Institute of Molecular Medicine in Finland, Genome
and Technology Center, Helsinki, Finland; the
3Department of Medicine,
Division of Nephrology, Helsinki University Central Hospital, Helsinki,
Finland; and
4The Medical Research Laboratories, Clinical Institute, Medical
Department M (Diabetes and Endocrinology), Aarhus University Hospital,
Aarhus, Denmark.
Corresponding author: Mari Kaunisto, mari.kaunisto@helsinki.ﬁ.
Received 28 October 2008 and accepted 25 March 2009.
Published ahead of print at http://diabetes.diabetesjournals.org on 14 April
2009. DOI: 10.2337/db08-1495.
*A complete list of the FinnDiane Study Group can be found in the online
appendix.
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
BRIEF REPORT
1710 DIABETES, VOL. 57, JULY 2009Here, we studied whether the MBL2 gene polymor-
phisms are associated with type 1 diabetes or diabetic
nephropathy by genotyping a dense set of SNPs in a large
well-characterized Finnish case-control sample and evalu-
ated the association between MBL concentration and
diabetic nephropathy.
RESEARCH DESIGN AND METHODS
We studied 1,297 patients with type 1 diabetes from the nationwide Finnish
Diabetic Nephropathy Study (FinnDiane). Patients were required to have an
onset of diabetes before 35 years of age and initiation of permanent insulin
treatment within 1 year of diagnosis. Patients were classiﬁed into four groups
based on the urinary albumin excretion rate (AER) or the presence of
end-stage renal disease (ESRD) (Table 1). Patients with normal AER were
required to have a duration of diabetes over 15 years. Serum concentration of
MBL was determined in 1,064 patients (available in the supplemental methods
at http://diabetes.diabetesjournals.org/cgi/content/full/db08-1495/DC1). For
nondiabetic control subjects, 701 Finnish blood donors (49% men; mean age
46.1 years) from all over the country were applied and compared with an age-
and sex-matched subgroup of patients with type 1 diabetes (n  701; 49% men;
mean age 43.9 years). The power of our study sample was calculated using the
Genetic Power Calculator (http://pngu.mgh.harvard.edu/purcell/gpc/) (21).
Study protocol was approved by the ethics committee of the Helsinki
University Central Hospital. Informed written consent was obtained from all
patients.
SNP selection and genotyping. We selected 17 SNPs using the HapMap
database release 21a (CEU) (http://www.hapmap.org/) and the Haploview
Tagger program (http://www.broad.mit.edu/mpg/haploview/index.php) (22)
from a 23-kb region covering the 6.3-kb MBL2 gene and the 5 untranslated
region and 3 untranslated region. SNPs were chosen to capture all known
HapMap SNPs having a minor allele frequency (MAF) 0.01 in the CEU
population with pairwise r
2  0.8. Additionally, three functional SNPs (allele
C, allele D, and variant H/L) were genotyped (supplementary Table 1). For
genotyping, see the supplemental methods in the online appendix.
Statistical analyses of MBL concentrations. Comparisons between groups
were performed using the Mann-Whitney U test because MBL concentrations
were not normally distributed. These analyses were done using the SPSS v.
15.0 software (SPSS, Chicago, IL).
Association analyses. Allele frequencies and genotype distributions for
single SNPs were compared between the control subjects and the matched
subset of patients with type 1 diabetes as well as between patients with
macroalbuminuria and patients with type 1 diabetes but normal AER. We also
compared patients having ESRD with patients with normal AER and com-
pared a combined group of patients with macroalbuminuria or ESRD with
patients with normal AER. An allelic association 
2 test and three genotypic
tests (general, dominant, and recessive models) were performed for each SNP.
Association of the SNPs with MBL concentration was studied using the
asymptotic Wald test. Additionally, analyses with adjustment for potential
confounders (age, sex, A1C, diabetes duration, and history of smoking) were
performed. The PLINK analysis program, version 1.00, was applied in all
analyses (http://pngu.mgh.harvard.edu/purcell/plink/) (23). For haplotype
association analyses, see the supplemental methods in the online appendix.
RESULTS
SNP genotyping. The 17 tag SNPs genotyped captured
the 68 HapMap SNPs having an MAF0.01 with a mean
pairwise r
2 of 0.97. The average distance between all of
the 20 studied SNPs is 1.2 kb. All SNPs were in Hardy-
Weinberg equilibrium (P  0.01) both in the healthy
control subjects (supplementary Table 1) and in type 1
diabetic patients (data not shown). Pairwise LD values
(r
2) between the SNPs are shown in supplementary Fig. 1.
The frequencies of the exon 1 variants were 0.13 (B), 0.06
(C), and 0.006 (D) in the healthy subjects, which is in line
with the previously published frequencies in the Finnish
population (17). Of the patients with diabetes, 30.6% were
heterozygous carriers of one of these variants (A/O geno-
type) and 5.8% were homozygotes or compound heterozy-
gotes (O/O genotype).
MBL concentrations. The median serum concentration
of MBL was higher in patients with macroalbuminuria
(1,881 	g/l [interquartile range 608–3,124]) than in patients
with normal AER (1,548 	g/l [514–2,635]); P  0.019 (Fig.
1). Supplementary Table 2 shows the distribution of the
MBL2 diplotypes and the corresponding median MBL
concentrations. As expected, the carriers of the exon 1
variants and the individuals homozygous for the X pro-
moter polymorphism had clearly reduced MBL concentra-
tions, with a median of 397 	g/l. When the patients were
stratiﬁed both by nephropathy status and MBL2 diplotype
TABLE 1
Clinical characteristics of the patients grouped by their nephropathy status
Normal AER Microalbuminuria Macroalbuminuria ESRD P
AER Criteria 
20 	g/min or 
30
mg/24 h
20 and 
200 	g/min or
30 and 
300 mg/24 h
200 	g/min or
300 mg/24 h
NA
n 477 276 366 178
Male/female 40/60 59/41* 59/41* 58/42* 
0.0001
Age (years) 42.5  10.1 37.3  10.9* 39.0  9.0* 42.2  7.5*‡ 
0.0001
Duration of diabetes (years) 28.5  7.1 25.0  9.4* 27.2  6.4§ 30.1  6.5‡ 
0.0001
Time to DNP (years) NA NA 18.3  6.3 17.1  5.1 0.039
BMI (kg/m
2) 24.8  2.9 25.7  3.5† 25.7  3.8† 23.9  3.5†‡ 
0.0001
SBP (mmHg) 132  16 136  17 144  19*‡ 154  22*‡ 
0.0001
DBP (mmHg) 78  98 1  10* 84  10*§ 88  11*‡ 
0.0001
Retinal laser treatment 29 48* 81*‡ 98*‡ 
0.0001
Hypertension 51 86* 98*‡ 97*‡ 
0.0001
Antihypertensive treatment 18 66* 95*‡ 92*‡ 
0.0001
A1C (%) 8.1  1.2 8.8  1.4* 9.0  1.6* 8.7  1.5* 
0.0001
AER (mg/24 h) 7 (1–85)* 59 (2–613)* 587 (4–8,348)*‡ — 
0.0001
eGFR (ml/min per 1.73 m
2) 89.8  18.1 95.7  25.3* 64.6  31.8*‡ — 
0.0001
Serum creatinine (	mol/l) 84 (43–144) 88 (35–194)† 127 (20–1,278)*‡ — 
0.0001
Data are means  SD, median (interquartile range), or percent unless otherwise indicated. Patients were classiﬁed into three groups based
on the AER in at least two of three consecutive overnight or 24-h urine collections. A fourth patient group consisted of patients on dialysis
(n  34) and patients who had received a kidney transplant (n  144) and were thus classiﬁed as having ESRD. The 24-h AER and serum
creatinine values were derived from the last central laboratory measurements. Therefore, single values may exceed or fall behind the
thresholds for the classiﬁcation due to effects of treatment. Estimated glomerular ﬁltration rate (eGFR) was calculated using the
Cockcroft-Gault formula adjusted for body surface area (ref. 20). *P 
 0.0001 versus normoalbuminuria. †P 
 0.01 versus normoalbuminuria.
‡P 
 0.0001 versus microalbuminuria. §P 
 0.01 versus microalbuminuria. P 
 0.0001 versus macroalbuminuria. ¶P 
 0.01 versus
macroalbuminuria. DBP, diastolic blood pressure; DNP, diabetic nephropathy; SBP, systolic blood pressure.
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uria had signiﬁcantly higher MBL concentrations than
patients with normal AER for two of the six (YA/YA: P 
0.0002; YA/YO: P  0.003) diplotype categories (supple-
mentary Table 2 and Fig. 2).
Association analyses between single SNP and type 1
diabetes. There were no signiﬁcant differences in allele
frequencies or genotype distributions between the patients
with type 1 diabetes and nondiabetic control subjects
(supplementary Table 3). Although nominal evidence of
allelic association (P  0.01–0.04) was seen for four SNPs
(rs930507, rs2384045, rs11003132, and rs11003137), the P
values did not remain signiﬁcant after correction for the
number of tests performed. Men and women were also
tested separately, but no signiﬁcant P values were
achieved (data not shown).
Association analyses between single SNPs and ne-
phropathy. Association analyses showed no signiﬁcant
differences in allele frequencies or genotype distribu-
tions between patients with macroalbuminuria and
patients with type 1 diabetes but normal AER (supple-
mentary Table 4). When patients with ESRD were
compared with patients with normal AER, signiﬁcant
evidence of association was observed for rs920727. The
MAF of this SNP was 0.19 in patients with normal AER
and 0.29 in patients with ESRD (P  0.00009). The
genotype distribution of this SNP was also signiﬁcantly
different between these groups (P  0.0002), with
homozygous individuals being more common among
ESRD patients (10 vs. 3%). The same SNP had a P value
of 0.006 in the genotypic test when a combined group of
patients with macroalbuminuria or ESRD was compared
with patients with normal AER. No other SNP provided
evidence of association in these analyses. The analyses
were also performed with adjustment for potential
confounders (supplementary Table 4). None of the SNPs
showed evidence of association with nephropathy after
the adjustment procedure.
Association analyses between single SNPs and MBL
concentrations. All SNPs, except rs10824793, were asso-
ciated with MBL concentration (supplementary Table 5).
The SNPs showing the strongest associations were
rs7899547 (P  3.0  10
81), rs1031101 (tagging the B
allele; P  8.0  10
76), rs2384045 (P  2.2  10
59), and
rs920727 (P  7.6  10
45). The promoter variants H/L
(rs11003125) and P/Q (tagged by rs920724) had P values of
8.8  10
25 and 6.1  10
10, respectively, whereas the
alleles C and D had P values of 1.5  10
7 and 9.0  10
19,
respectively. The analyses were also performed with ad-
justment for potential confounders (supplementary Table
5).
Haplotype and diplotype analyses. The haplotypes con-
structed using the Haploview program were studied for
association with type 1 diabetes and diabetic nephropathy.
The results did not improve compared with the single SNP
results. The distribution of the MBL2 diplotypes, diplotype
categories, and the high- and low-MBL genotypes in each
patient group is presented in Table 2. There were no
differences in the frequency of the high-MBL genotypes
between the patients with normal AER (0.60) and mac-
roalbuminuria (0.61; P  0.39). Similarly, when the distri-
bution of the six diplotype categories was analyzed, no
differences were seen (P  0.63).
DISCUSSION
Our study showed no evidence of association between the
MBL2 SNPs and type 1 diabetes, although weak associa-
tion signals (uncorrected P  0.01–0.04) were seen for
four SNPs. This is in accordance with most of the previous
studies (1,6,17,18). Importantly, using tag SNPs, we have
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FIG. 1. Box plot diagram showing the distribution of serum MBL
concentrations, for patients with type 1 diabetes, stratiﬁed by ne-
phropathy status. Black horizontal lines, median values; , interquar-
tile ranges; E, outliers. The median serum concentration of MBL was
higher in patients with macroalbuminuria (median 1,881 g/l [inter-
quartile range 608–3,124]) than in patients with normal AER (1,548
g/l [514–2,635]), P  0.019. The median concentration was 1,645 g/l
(531–3,220) in patients with microalbuminuria and 1,359 g/l (343–
2798) in patients with ESRD, P  0.17 and P  0.45, respectively,
compared with patients with normal AER.
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FIG. 2. Distribution of serum MBL concentrations in patients with
normal AER and patients with macroalbuminuria, stratiﬁed by the
MBL2 diplotype.
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ings, whereas the other studies addressed only the func-
tional exon 1 variants.
In a Danish study (6), genotypes producing high MBL
concentrations were more common in patients having
diabetic nephropathy than in patients with normal AER.
We found no evidence of such an association, although our
study sample was about double the size (6). Furthermore,
we thoroughly studied association between both single
MBL2 SNPs and haplotypes and nephropathy, but all the
results were negative.
In accordance with previous studies (6,7), we showed
that the median serum MBL concentration was signiﬁ-
cantly higher in patients with macroalbuminuria compared
with the patients with normal AER. This result persisted
even when the patients were stratiﬁed by the MBL diplo-
type categories, although the difference was signiﬁcant in
only two of them. Thus, it seems that the high serum MBL
concentration in patients with nephropathy is likely to
reﬂect some still unknown pathogenic event such as
chronic low-grade inﬂammation. Further studies are
needed to resolve whether elevated MBL concentrations
are a marker associated with some other contributing
factor or a consequence of nephropathy or diabetic micro-
vascular complications in general.
The minor allele of the SNP rs920727 was more common
in ESRD patients than in the other patients 0.29 vs.
0.19–0.20). Furthermore, the frequency of the high-MBL
genotypes was somewhat lower in the ESRD patients than
in the other groups (0.54 vs. 0.60–0.61), potentially ex-
plaining the relatively low MBL concentration in the ESRD
patients. However, we do not consider these differences as
an indication of a causal association with ESRD pheno-
type. Most likely they are due to chance or even signs of
selective mortality. Supporting this hypothesis, evidence
exists that mortality of patients with type 2 diabetes is
higher among individuals with an MBL concentration
1,000 	g/l (24). Moreover, most of the ESRD patients in
our study have received a kidney transplant, and graft
TABLE 2
Distribution of the MBL2 genotypes within the different patient groups
MBL2 diplotype
Normal
AER Microalbuminuria Macroalbuminuria ESRD
High-MBL genotypes YA/YA HYPA/HYPA 63 37 58 19
HYPA/LYQA 70 28 46 16
HYPA/LYPA 16 13 12 13
LYQA/LYQA 19 8 13 5
LYPA/LYQA 8 6 7 5
LYPA/LYPA 2 2 0 1
Total 178 (37.6) 94 (34.2) 136 (37.3) 59 (33.9)
YA/XA HYPA/LXPA 70 41 54 24
LYQA/LXPA 29 23 27 9
LYPA/LXPA 7 10 6 2
Total 106 (22.4) 74 (26.9) 87 (23.8) 35 (20.1)
Total 284 (59.9) 168 (61.1) 223 (61.1) 94 (54.0)
Low-MBL genotypes XA/XA LXPA/LXPA 27 (5.7) 12 (4.4) 12 (3.3) 8 (4.6)
YA/YO HYPA/LYPB 46 24 27 19
LYQA/LYPB 20 11 18 7
LYPA/LYPB 3 4 2 4
HYPA/LYQC 3 3 1 1
LYQA/LYQC 3 1 1 1
LYPA/LYQC 1 1 1 0
HYPA/HYPD 21 10 18 8
LYQA/HYPD 9 8 13 4
LYPA/HYPD 3 2 2 0
Total 109 (23.0) 64 (23.3) 83 (22.7) 44 (25.3)
XA/YO LXPA/LYPB 24 6 18 8
LXPA/LYQC 2 0 1 2
LXPA/HYPD 8 9 8 3
Total 34 (7.2) 15 (5.5) 27 (7.4) 13 (7.5)
YO/YO LYPB/LYPB 8 4 9 6
LYPB/LYQC 1 0 0 3
LYPB/HYPD 9 8 5 2
HYPD/HYPD 2 4 1 4
LYQC/HYPD 0 0 5 0
Total 20 (4.2) 16 (5.8) 20 (5.5) 15 (8.6)
Total 190 (40.1) 107 (38.9) 142 (38.9) 80 (46.0)
All 474 (100) 275 (100) 365 (100) 174 (100)
Data are n or n (percent). The MBL2 haplotypes were determined based on the co-occurrence of the three promoter variants (H/L,
rs11003125; X/Y, rs7096206; and P/Q, rs7095891) and the three exon 1 variants (B, rs1800450; C, rs1800451; and D, rs5030737). Diplotypes were
grouped into six categories (YA/YA, YA/XA, XA/XA, YA/YO, XA/YO, and YO/YO) based on the X/Y polymorphism and the presence of any of
the exon 1 variants (B, C, and D), collectively designated with O, and further into low- and high-MBL genotypes. There were no differences
in the frequency of the high-MBL genotypes between the patients with normal AER and macroalbuminuria. However, the frequency of the
high-MBL genotypes within the group of ESRD patients (0.54) was lower than in patients with normal AER (0.60), although this difference
was not signiﬁcant (P  0.10).
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MBL concentrations (25).
Many of the SNPs showing strong association with MBL
concentration (including the ESRD-associated rs920727)
did not belong to the group of SNPs forming the common
MBL2 haplotypes. Some of these variants may have an
independent effect on the MBL concentration or tag other
still unknown functional variants. However, this some-
what surprising association pattern can mainly be ex-
plained by LD between the associated and haplotype-
forming SNPs (supplementary Table 6).
Our study sample has a reasonably high power to detect
associations with relatively common SNPs (population
frequency 20%) with modest effects. The previously
described higher median MBL concentration in patients
with macroalbuminuria (6,7) was evident also in our
sample. We have thoroughly covered the common varia-
tion within the MBL2 gene in carefully characterized
Finnish type 1 diabetic patients. We conclude that al-
though most of the MBL2 SNPs studied were associated
with the MBL concentration, neither any single SNP nor
any of their haplotype combinations confer risk of type 1
diabetes or diabetic nephropathy.
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